Das Mammakarzinom beim Mann: Eine Herausforderung für den Urologen
Standard
Das Mammakarzinom beim Mann: Eine Herausforderung für den Urologen. / Hofer, C; Schmalfeldt, B; Gschwend, J E; Herkommer, K.
In: UROLOGE, Vol. 49, No. 9, 09.2010, p. 1142, 1144-8.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Das Mammakarzinom beim Mann: Eine Herausforderung für den Urologen
AU - Hofer, C
AU - Schmalfeldt, B
AU - Gschwend, J E
AU - Herkommer, K
PY - 2010/9
Y1 - 2010/9
N2 - Male breast cancer (male BC) accounts for <1% of all cancers in men, showing an increasing incidence with a peak in the sixth decade. Overall, men experience a worse prognosis than women, probably due to an advanced stage together with the higher age at diagnosis of male patients. Major risk factors for developing male BC include clinical disorders involving hormonal imbalances (excess of estrogen or a deficiency of testosterone as seen in patients with Klinefelter syndrome) and a positive family history for breast cancer. About 90% of male BC are invasive ductal carcinomas. Standard treatment for localized cancer is surgical removal. Adjuvant radiation and systemic therapy are the same as in women with breast cancer. Male BC expresses hormone receptors in about 90% of cases; therefore, tamoxifen is a therapeutic option. A future challenge for the urologist or andrologist is to diagnose the disease at an early stage to improve prognosis.
AB - Male breast cancer (male BC) accounts for <1% of all cancers in men, showing an increasing incidence with a peak in the sixth decade. Overall, men experience a worse prognosis than women, probably due to an advanced stage together with the higher age at diagnosis of male patients. Major risk factors for developing male BC include clinical disorders involving hormonal imbalances (excess of estrogen or a deficiency of testosterone as seen in patients with Klinefelter syndrome) and a positive family history for breast cancer. About 90% of male BC are invasive ductal carcinomas. Standard treatment for localized cancer is surgical removal. Adjuvant radiation and systemic therapy are the same as in women with breast cancer. Male BC expresses hormone receptors in about 90% of cases; therefore, tamoxifen is a therapeutic option. A future challenge for the urologist or andrologist is to diagnose the disease at an early stage to improve prognosis.
KW - Antineoplastic Agents
KW - Breast Neoplasms, Male
KW - Diagnostic Techniques, Urological
KW - Humans
KW - Male
KW - Prevalence
KW - Tamoxifen
U2 - 10.1007/s00120-010-2356-y
DO - 10.1007/s00120-010-2356-y
M3 - SCORING: Zeitschriftenaufsatz
C2 - 20706705
VL - 49
SP - 1142, 1144-8
JO - UROLOGE
JF - UROLOGE
SN - 0340-2592
IS - 9
ER -
